259 related articles for article (PubMed ID: 24265052)
1. Craniovertebral junction pathological features and their management in the mucopolysaccharidoses.
Sganzerla EP; Giussani C; Grimaldi M; Parini R; Ingelmo P; Trezza A; Visocchi M
Adv Tech Stand Neurosurg; 2014; 40():313-31. PubMed ID: 24265052
[TBL] [Abstract][Full Text] [Related]
2. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
[TBL] [Abstract][Full Text] [Related]
3. Therapies for the bone in mucopolysaccharidoses.
Tomatsu S; Alméciga-Díaz CJ; Montaño AM; Yabe H; Tanaka A; Dung VC; Giugliani R; Kubaski F; Mason RW; Yasuda E; Sawamoto K; Mackenzie W; Suzuki Y; Orii KE; Barrera LA; Sly WS; Orii T
Mol Genet Metab; 2015 Feb; 114(2):94-109. PubMed ID: 25537451
[TBL] [Abstract][Full Text] [Related]
4. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses.
Muenzer J
Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732
[TBL] [Abstract][Full Text] [Related]
5. Current and new therapies for mucopolysaccharidoses.
Penon-Portmann M; Blair DR; Harmatz P
Pediatr Neonatol; 2023 Feb; 64 Suppl 1():S10-S17. PubMed ID: 36464587
[TBL] [Abstract][Full Text] [Related]
6. Unique medical issues in adult patients with mucopolysaccharidoses.
Mitchell J; Berger KI; Borgo A; Braunlin EA; Burton BK; Ghotme KA; Kircher SG; Molter D; Orchard PJ; Palmer J; Pastores GM; Rapoport DM; Wang RY; White K
Eur J Intern Med; 2016 Oct; 34():2-10. PubMed ID: 27296591
[TBL] [Abstract][Full Text] [Related]
7. Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets.
Leal AF; Benincore-Flórez E; Rintz E; Herreño-Pachón AM; Celik B; Ago Y; Alméciga-Díaz CJ; Tomatsu S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613919
[TBL] [Abstract][Full Text] [Related]
8. Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies.
Nan H; Park C; Maeng S
Biomed Res Int; 2020; 2020():2408402. PubMed ID: 33344633
[No Abstract] [Full Text] [Related]
9. [Principles of therapeutic approaches for mucopolysaccharidoses].
Caillaud C
Arch Pediatr; 2014 Jun; 21 Suppl 1():S39-45. PubMed ID: 25063383
[TBL] [Abstract][Full Text] [Related]
10. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.
Banecka-Majkutewicz Z; Jakóbkiewicz-Banecka J; Gabig-Cimińska M; Węgrzyn A; Węgrzyn G
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):461-8. PubMed ID: 22949095
[TBL] [Abstract][Full Text] [Related]
11. Transplant outcomes in mucopolysaccharidoses.
Prasad VK; Kurtzberg J
Semin Hematol; 2010 Jan; 47(1):59-69. PubMed ID: 20109613
[TBL] [Abstract][Full Text] [Related]
12. Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses.
Cotugno G; Tessitore A; Capalbo A; Annunziata P; Strisciuglio C; Faella A; Aurilio M; Di Tommaso M; Russo F; Mancini A; De Leonibus E; Aloj L; Auricchio A
Hum Gene Ther; 2010 May; 21(5):555-69. PubMed ID: 20021231
[TBL] [Abstract][Full Text] [Related]
13. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses.
Kakkis E; Marsden D
Mol Genet Metab; 2020 May; 130(1):7-15. PubMed ID: 32224020
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments.
Sawamoto K; Stapleton M; Alméciga-Díaz CJ; Espejo-Mojica AJ; Losada JC; Suarez DA; Tomatsu S
Drugs; 2019 Jul; 79(10):1103-1134. PubMed ID: 31209777
[TBL] [Abstract][Full Text] [Related]
15. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.
Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.
Peck SH; Casal ML; Malhotra NR; Ficicioglu C; Smith LJ
Mol Genet Metab; 2016 Aug; 118(4):232-43. PubMed ID: 27296532
[TBL] [Abstract][Full Text] [Related]
17. Substrate reduction therapies for mucopolysaccharidoses.
Jakóbkiewicz-Banecka J; Piotrowska E; Gabig-Cimińska M; Borysiewicz E; Słomińska-Wojewódzka M; Narajczyk M; Węgrzyn A; Węgrzyn G
Curr Pharm Biotechnol; 2011 Nov; 12(11):1860-5. PubMed ID: 21902626
[TBL] [Abstract][Full Text] [Related]
18. Radiologic and neuroradiologic findings in the mucopolysaccharidoses.
Lachman R; Martin KW; Castro S; Basto MA; Adams A; Teles EL
J Pediatr Rehabil Med; 2010; 3(2):109-18. PubMed ID: 21791838
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell transplantation effects on spinal cord compression in Hurler.
Ferrara G; Maximova N; Zennaro F; Gregori M; Tamaro P
Pediatr Transplant; 2014 May; 18(3):E96-9. PubMed ID: 24483599
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for the treatment of mucopolysaccharidoses.
Giugliani R; Federhen A; Vairo F; Vanzella C; Pasqualim G; da Silva LM; Giugliani L; de Boer AP; de Souza CF; Matte U; Baldo G
Expert Opin Emerg Drugs; 2016; 21(1):9-26. PubMed ID: 26751109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
